Clinical Research Directory

CML Pediatric ITK Response According to Molecular Identification at Diagnosis

Sponsor: University Hospital, Bordeaux

Summary

Treatment of chronic myeloid leukemia (CML) has been revolutionized by tyrosine kinase inhibitor (TKI). Nevertheless, case of failure and suboptimal response are still observed even in children. Pediatric CML is a rare disease and differs from adult in terms of disease presentation and treatment response underlying a likely different CML biology. Molecular mechanisms that induce resistance to TKI are still poorly characterized except mutations in the tyrosine kinase domain of BCR::ABL1. We propose to search for a molecular signature to predict the response to TKI in the pediatric population.

Official title: CML Pediatric ITK Response According to Molecular Identification at Diagnosis (CML Piramid

Key Details

Conditions

Interventions

Locations (1)